Diagnostic efficacy and influencing factors of non-invasive liver fibrosis scores in chronic hepatitis B fibrosis: Cross-sectional study

Table 6 Aspartate aminotransferase to platelet ratio index, fibrosis-4 index, aspartate aminotransferase to alanine aminotransferase ratio and gamma-glutamyl transferase to platelet ratio based on FibroScan results (n = 627), median (interquartile range)

LSM	APRI	FIB-4	AST/ALT	GPR
F0	0.835 (0.500-1.672)	1.690 (0.992-2.473)	0.670 (0.487-1.008)	0.355 (0.217-0.653)
F1	1.080 (0.500-2.110)	1.600 (0.990-2.950)	0.640 (0.490-0.950)	0.510 (0.250-1.030)
F2	1.500 (0.625-3.980)	2.270 (1.380-3.655)	0.630 (0.465-0.925)	0.830 (0.455-1.710)
F3	2.150 (1.270-5.860)	4.690 (2.500-7.960)	0.830 (0.570-1.160)	1.600 (0.820-2.590)
F4	5.295 (2.212-11.165)	6.320 (3.513-10.688)	0.880 (0.540-1.333)	2.210 (1.132-3.980)
P value	< 0.001	< 0.001	< 0.001	< 0.001

The Kruskal-Wallis test was used to compare the overall differences in indicators across different FibroScan stages. LSM: Liver stiffness measurement; APRI: Aspartate aminotransferase to platelet ratio index; GPR: Gamma-glutamyl transferase to platelet ratio index; FIB-4: Fibrosis-4 index; AST/ALT: Aspartate aminotransferase to alanine aminotransferase ratio.